Cargando…

Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes

INTRODUCTION: Inflammatory bowel disease (IBD) consisting of Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory conditions affecting the gastrointestinal tract. Infliximab (IFX) is a chimeric anti‐tumor necrosis factor antibody used to treat moderate to severe IBD. Eosinophils ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Zabrowski, Douglas, Abraham, Danielle, Rosenthal, Geoffrey, Kader, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411706/
https://www.ncbi.nlm.nih.gov/pubmed/32782950
http://dx.doi.org/10.1002/jgh3.12308
_version_ 1783568440322162688
author Zabrowski, Douglas
Abraham, Danielle
Rosenthal, Geoffrey
Kader, Howard
author_facet Zabrowski, Douglas
Abraham, Danielle
Rosenthal, Geoffrey
Kader, Howard
author_sort Zabrowski, Douglas
collection PubMed
description INTRODUCTION: Inflammatory bowel disease (IBD) consisting of Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory conditions affecting the gastrointestinal tract. Infliximab (IFX) is a chimeric anti‐tumor necrosis factor antibody used to treat moderate to severe IBD. Eosinophils are commonly found in chronically inflamed tissues in IBD. Peripheral eosinophilia (PE) was previously implicated as a marker of disease severity at diagnosis. The main aim of this study was to investigate whether in IBD patients on IFX, development of PE is associated with adverse outcomes and poor IFX efficacy. METHODS: A comprehensive retrospective chart review of IBD patients on IFX (January 2006 to July 2015) treated at a tertiary pediatric IBD center was performed. Data was collected at time specified points over a 24 month period and included demographics, atopy, disease severity, development of PE, human antichimeric antibodies (HACA), infusion reactions, cancer, psoriasis, and loss of clinical response. RESULTS: One hundred twenty‐one IBD patients starting IFX (67 male), mean age of 12.4 years (range 4–22 years old), met inclusion criteria. Of them, 36.3% had ≥1 PE episode (CD: 25 male, 11 female; UC: 6 male, 2 female). Mean absolute eosinophil count (AEC) did not change over time. PE was associated with clinically active disease. Among patients who developed PE, adverse outcomes were not significantly different versus those who did not have PE. CONCLUSIONS: In a cohort of primarily pediatric IBD patients on IFX, PE was associated with clinically active disease; however, PE was not related to increased incidence of adverse outcomes or loss of drug efficacy.
format Online
Article
Text
id pubmed-7411706
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wiley Publishing Asia Pty Ltd
record_format MEDLINE/PubMed
spelling pubmed-74117062020-08-10 Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes Zabrowski, Douglas Abraham, Danielle Rosenthal, Geoffrey Kader, Howard JGH Open Original Articles INTRODUCTION: Inflammatory bowel disease (IBD) consisting of Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory conditions affecting the gastrointestinal tract. Infliximab (IFX) is a chimeric anti‐tumor necrosis factor antibody used to treat moderate to severe IBD. Eosinophils are commonly found in chronically inflamed tissues in IBD. Peripheral eosinophilia (PE) was previously implicated as a marker of disease severity at diagnosis. The main aim of this study was to investigate whether in IBD patients on IFX, development of PE is associated with adverse outcomes and poor IFX efficacy. METHODS: A comprehensive retrospective chart review of IBD patients on IFX (January 2006 to July 2015) treated at a tertiary pediatric IBD center was performed. Data was collected at time specified points over a 24 month period and included demographics, atopy, disease severity, development of PE, human antichimeric antibodies (HACA), infusion reactions, cancer, psoriasis, and loss of clinical response. RESULTS: One hundred twenty‐one IBD patients starting IFX (67 male), mean age of 12.4 years (range 4–22 years old), met inclusion criteria. Of them, 36.3% had ≥1 PE episode (CD: 25 male, 11 female; UC: 6 male, 2 female). Mean absolute eosinophil count (AEC) did not change over time. PE was associated with clinically active disease. Among patients who developed PE, adverse outcomes were not significantly different versus those who did not have PE. CONCLUSIONS: In a cohort of primarily pediatric IBD patients on IFX, PE was associated with clinically active disease; however, PE was not related to increased incidence of adverse outcomes or loss of drug efficacy. Wiley Publishing Asia Pty Ltd 2020-02-07 /pmc/articles/PMC7411706/ /pubmed/32782950 http://dx.doi.org/10.1002/jgh3.12308 Text en © 2020 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Zabrowski, Douglas
Abraham, Danielle
Rosenthal, Geoffrey
Kader, Howard
Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes
title Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes
title_full Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes
title_fullStr Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes
title_full_unstemmed Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes
title_short Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes
title_sort development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411706/
https://www.ncbi.nlm.nih.gov/pubmed/32782950
http://dx.doi.org/10.1002/jgh3.12308
work_keys_str_mv AT zabrowskidouglas developmentofperipheraleosinophiliaininflammatoryboweldiseasepatientsoninfliximabtreatedatatertiarypediatricinflammatoryboweldiseasecenterisassociatedwithclinicallyactivediseasebutdoesnotresultinlossofefficacyoradverseoutcomes
AT abrahamdanielle developmentofperipheraleosinophiliaininflammatoryboweldiseasepatientsoninfliximabtreatedatatertiarypediatricinflammatoryboweldiseasecenterisassociatedwithclinicallyactivediseasebutdoesnotresultinlossofefficacyoradverseoutcomes
AT rosenthalgeoffrey developmentofperipheraleosinophiliaininflammatoryboweldiseasepatientsoninfliximabtreatedatatertiarypediatricinflammatoryboweldiseasecenterisassociatedwithclinicallyactivediseasebutdoesnotresultinlossofefficacyoradverseoutcomes
AT kaderhoward developmentofperipheraleosinophiliaininflammatoryboweldiseasepatientsoninfliximabtreatedatatertiarypediatricinflammatoryboweldiseasecenterisassociatedwithclinicallyactivediseasebutdoesnotresultinlossofefficacyoradverseoutcomes